European Society for Medical Oncology

Like the treatments were quite, we've got all these targeted mutations and targeted drugs and they're changing rapidly.

Every ASCO, every ESMO, you're getting sort of newer targeted drugs.

And I'd love to sort of see what your thoughts are for that cohort of patients moving forward.

So, you know, each year we're getting the next generation of sort of EGFR treatments targets? And what do you see for this cohort in the next five or 10 years? Do you see like, yes, we've got electinib and lalatinib and like incredible elk drugs as well, but like, what's the shift that you're going to see in this cohort of patients? Have you got any predictions?

And so that's what I'm using as I'm pulling it up because it's real time and I pull it up.

So what do I see about KTTA that's really important? What I see is that I like specific dates, right? Well, the specific date, they're going to be giving a presentation at ESMO on October 23rd.

That's their conference presentation.

So, again, you know, this program that they're on, FDA, FastTrack, Rare Pediatric Designations, and NF1, PN1, they have this interim data at ESMO on October 23rd.

And, you know, it's going to be huge, the ESMO Congress 2026.

So one thing I want to say, they've shown previous data in their first ever human dose escalation, advanced cancer study at PAS004.

They showed disease control of 71.4% among efficacy of valuable patients with BRAF mutation tumors, which is pretty significant.

So I'm looking forward to seeing what they come out with at ESMO.

to second-generation KRAS inhibitor very soon, I'm sure.

Yeah, that's what I was going to say, that not too long from now, I think specifically at the ESMO meeting, Sotirisib and Adagrasib are going to become the cruzotinib, a historical interest, and we'll get into that in a second.

Josh, here are some of the questions we asked.

Again, these are the agents we have available.

It looks like the first trial.

And you don't see this too often.

Comparing agents is about to be presented at ESMO.

Solange was telling me very likely it's going to be presented at ESMO.

24-month overall survival, 75% versus 70% hazard ratio 0.78. That just reached statistical significance.

The ESMO magnitude of clinical benefit scale, shout out to Professor Jackson if he's listening, who's a big fan of that scale.

gave it a score of A, so A represents a substantial benefit.

So we'll put a link to the study for people if they want to refer to some more information.

The NCCN and ESMO both supported the use of this approach in their guidelines.

As I said, for people who treat GI cancers regularly, They'll now be actively discussing this as an option for patients with resectable disease in their MBTs and making a decision whether to use this approach or not.

Excellent.

Yeah.

We hope to present this at ESMO.

Uh, four hundred patients were randomized three to one to prostatectomy alone or what I'm calling the Proteus regimen.

So, uh, the primary event, the primary, uh, measurement is a little bit different.

It's event-free survival at three years, so not quite as rigorous as the primary Proteus study because event-free th- survival includes PSA, um, and it's three years, not five years.

But yeah, we're excited to present that at, at ESMO, and I would predict that'll be a very, very positive study, um, sub-study.

Yeah.

The, the three years to-